Clinical trials are undergoing sweeping transformation, with new and emerging technologies introducing new modalities and regulators rethinking the rules in response. This shift has been hastened by the necessities of pandemic-era operating constraints and a growing attentiveness to the patient experience and the need for a more representative pool of participants.
Meanwhile, the availability of real world and other data sets is enabling clinical trial sponsors to identify trial sites, investigators and protocols with much greater precision, potentially enabling them to speed products to market and better meet the needs of their patients.
In this webinar, we will explore the following questions of concern to trial sponsors: